Please login to the form below

CDK4/6 inhibitor

This page shows the latest CDK4/6 inhibitor news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

growth factor receptor 2 (HER2)-low or negative locally advanced or metastatic breast cancer, following recurrence or progression on or after endocrine therapy (with or without a CDK4/6 inhibitor). ... However, resistance to CDK4/6 inhibitors and current

Latest news

NICE recommends Novartis’ Piqray in combination with Faslodex for advanced breast cancer patients

2 negative (HER2-), PIK3CA-mutated locally advanced or metastatic breast cancer, that has progressed after endocrine and CDK4/6 inhibitor therapy. ... following endocrine therapy as monotherapy, but the licence did not include patients that have received
FDA approves Eli Lilly’s Verzenio in high risk early breast cancer

Over time, the collective results of the Verzenio clinical development programme have demonstrated a differentiated CDK4/6 inhibitor profile, and the landmark data from the monarchE trial that supported this new ... Verzenio is the first and only CDK4/6
Strong five-year survival data for Kisqali in breast cancer

Novartis has presented a final analysis of its phase 3 MONALEESA-2 trial showing a survival benefit of more than 12 months for its CDK4/6 inhibitor, Kisqali (ribociclib) in combination ... This means Kisqali is the only CDK4/6 inhibitor with proven
Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

Outside the US, CDK4/6 inhibitor Ibrance was also up by 21%, while sales of tyrosine kinase inhibitor (TKI) Inlyta also increased by 29% globally following increased adoption in the US
Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

ARV-471 is also being studied in a phase 1b combination study alongside Pfizer’s blockbuster CDK4/6 inhibitor Ibrance (palbociclib). ... Building on Pfizer’s established leadership position in breast cancer science and CDK4/6 inhibition, we are

More from news
Approximately 2 fully matching, plus 32 partially matching documents found.

Latest Intelligence

Putting the ovation into innovation: trends from ESMO

However, the data is very impressive in patients no longer responding to checkpoint inhibitor blockade and building on this technology may bring more accessible treatments. ... The first approved CDK4/6 inhibitor, palbociclib (IBRANCE) showcased the most

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Senior Medical Copywriter - Highly Awarded Advertising Agency: £50,000 - £60,000 yearly

Account Manager, Healthcare Marketing Creative Agency, Fixed ter...: Highly competitive salary

Account Manager, 6 month contract, Healthcare Brand communicatio...: Highly competitive salary

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Home Based Account Manager, Medical Communications, UK, Pharma/M...: Highly competitive salary

Account Director, Healthcare Marketing Creative Agency, Fixed te...: Highly competitive salary

No results were found

PMHub

Add my company

Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Whitepaper: Closing the gap with compelling healthcare communications: Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
Healing the Healers: Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs: It’s not a question of ‘if,’ it’s a question of ‘when.’...

Email:
Password:

Please login to the form below

CDK4/6 inhibitor

Subscribe to our email news alerts

Quick links